Crohn's Disease in
the Clinical Setting
About CIMZIA®
Dosing and
Administration
Clinical Trials Overview
Patient Support
Safety Information
Resources
For Patients & Caregivers
Prescribing Information


This site is intended for
US residents.

Preparation and Administration of CIMZIA Using the Prefilled Syringe

Patients who are capable may self-inject CIMZIA using the prefilled syringe after proper training in subcutaneous injection and if a physician determines that it is appropriate. Patients who self-inject CIMZIA will require medical follow up, as necessary.

Patients using CIMZIA should be instructed to inject the full amount in the syringe, 200 mg (1 mL), according to the directions provided in the for use in the medication guide.

Features of the CIMZIA prefilled syringe

UCB, the pharmaceutical maker of CIMZIA, partnered with OXO GOOD GRIPS to design a syringe that would be easy to use. OXO GOOD GRIPS is the consumer products company dedicated to providing innovative products that make everyday living easier.

The founder of OXO® was well aware of the problem some people have gripping and using everyday items, because his wife had arthritis. Because of this, he designed products that would be easier for all people to use. For OXO, this means designing products for young and old, male and female, left- and right-handed people.

The design of the syringe was focused on making it easy to use.

CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
For more information 1.866.4.CIMZIA
CIMZIA